111 related articles for article (PubMed ID: 25544686)
1. Evaluating the risk of phospholipidosis using a new multidisciplinary pipeline approach.
Goracci L; Buratta S; Urbanelli L; Ferrara G; Di Guida R; Emiliani C; Cross S
Eur J Med Chem; 2015 Mar; 92():49-63. PubMed ID: 25544686
[TBL] [Abstract][Full Text] [Related]
2. In Silico Studies of the Relationship Between Chemical Structure and Drug Induced Phospholipidosis.
Przybylak KR; Cronin MT
Mol Inform; 2011 May; 30(5):415-29. PubMed ID: 27467088
[TBL] [Abstract][Full Text] [Related]
3. Cationic amphiphilic drug-induced phospholipidosis.
Halliwell WH
Toxicol Pathol; 1997; 25(1):53-60. PubMed ID: 9061852
[TBL] [Abstract][Full Text] [Related]
4. Drug-induced phospholipidosis is caused by blockade of mannose 6-phosphate receptor-mediated targeting of lysosomal enzymes.
Ikeda K; Hirayama M; Hirota Y; Asa E; Seki J; Tanaka Y
Biochem Biophys Res Commun; 2008 Dec; 377(1):268-74. PubMed ID: 18840403
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the phospholipidogenic potential of 4(1H)-pyridone antimalarial derivatives.
Almela MJ; Torres PA; Lozano S; Herreros E
Toxicol In Vitro; 2009 Dec; 23(8):1528-34. PubMed ID: 19540329
[TBL] [Abstract][Full Text] [Related]
6. Detection of metabolic activation leading to drug-induced phospholipidosis in rat hepatocyte spheroids.
Takagi M; Sanoh S; Santoh M; Ejiri Y; Kotake Y; Ohta S
J Toxicol Sci; 2016 Feb; 41(1):155-64. PubMed ID: 26763403
[TBL] [Abstract][Full Text] [Related]
7. Why are most phospholipidosis inducers also hERG blockers?
Slavov S; Stoyanova-Slavova I; Li S; Zhao J; Huang R; Xia M; Beger R
Arch Toxicol; 2017 Dec; 91(12):3885-3895. PubMed ID: 28551711
[TBL] [Abstract][Full Text] [Related]
8. Identification of drugs inducing phospholipidosis by novel in vitro data.
Muehlbacher M; Tripal P; Roas F; Kornhuber J
ChemMedChem; 2012 Nov; 7(11):1925-34. PubMed ID: 22945602
[TBL] [Abstract][Full Text] [Related]
9. Different Sensitivity of Macrophages to Phospholipidosis Induction by Amphiphilic Cationic Drugs.
Öhlinger K; Absenger-Novak M; Meindl C; Ober J; Fröhlich E
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33182310
[TBL] [Abstract][Full Text] [Related]
10. Computational identification of a phospholipidosis toxicophore using (13)C and (15)N NMR-distance based fingerprints.
Slavov SH; Wilkes JG; Buzatu DA; Kruhlak NL; Willard JM; Hanig JP; Beger RD
Bioorg Med Chem; 2014 Dec; 22(23):6706-6714. PubMed ID: 25228124
[TBL] [Abstract][Full Text] [Related]
11. Hydrophilic interaction chromatography with a focus on the drug-phosphate interaction in drug screening to determine the phospholipidosis induction risk.
Okamoto H; Hamaguchi R; Kuroda Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Apr; 1051():33-40. PubMed ID: 28285021
[TBL] [Abstract][Full Text] [Related]
12. Predicting in vivo phospholipidosis-inducing potential of drugs by a combined high content screening and in silico modelling approach.
Bauch C; Bevan S; Woodhouse H; Dilworth C; Walker P
Toxicol In Vitro; 2015 Apr; 29(3):621-30. PubMed ID: 25668432
[TBL] [Abstract][Full Text] [Related]
13. Construction and Consensus Performance of (Q)SAR Models for Predicting Phospholipidosis Using a Dataset of 743 Compounds.
Orogo AM; Choi SS; Minnier BL; Kruhlak NL
Mol Inform; 2012 Oct; 31(10):725-39. PubMed ID: 27476455
[TBL] [Abstract][Full Text] [Related]
14. From the Cover: Potentiation of Drug-Induced Phospholipidosis In Vitro through PEGlyated Graphene Oxide as the Nanocarrier.
Yang L; Zhong X; Li Q; Zhang X; Wang Y; Yang K; Zhang LW
Toxicol Sci; 2017 Mar; 156(1):39-53. PubMed ID: 28013220
[TBL] [Abstract][Full Text] [Related]
15. In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies.
Nioi P; Perry BK; Wang EJ; Gu YZ; Snyder RD
Toxicol Sci; 2007 Sep; 99(1):162-73. PubMed ID: 17567588
[TBL] [Abstract][Full Text] [Related]
16. Relationship between in vitro phospholipidosis assay using HepG2 cells and 2-week toxicity studies in rats.
Miyamoto S; Matsumoto A; Mori I; Horinouchi A
Toxicol Mech Methods; 2009 Oct; 19(8):477-85. PubMed ID: 19793005
[TBL] [Abstract][Full Text] [Related]
17. Phospholipidosis effect of drugs by adsorption into lipid monolayers.
Ceccarelli M; Germani R; Massari S; Petit C; Nurisso A; Wolfender JL; Goracci L
Colloids Surf B Biointerfaces; 2015 Dec; 136():175-84. PubMed ID: 26387069
[TBL] [Abstract][Full Text] [Related]
18. A role for lysosomal phospholipase A2 in drug induced phospholipidosis.
Abe A; Hiraoka M; Shayman JA
Drug Metab Lett; 2007 Jan; 1(1):49-53. PubMed ID: 19356018
[TBL] [Abstract][Full Text] [Related]
19. Evaluation and validation of multiple cell lines and primary mouse macrophages to predict phospholipidosis potential.
LeCureux L; Cheng CS; Herbst J; Reilly TP; Lehman-McKeeman L; Otieno M
Toxicol In Vitro; 2011 Dec; 25(8):1934-43. PubMed ID: 21767630
[TBL] [Abstract][Full Text] [Related]
20. A cell-based approach for the early assessment of the phospholipidogenic potential in pharmaceutical research and drug development.
Casartelli A; Bonato M; Cristofori P; Crivellente F; Dal Negro G; Masotto I; Mutinelli C; Valko K; Bonfante V
Cell Biol Toxicol; 2003 Jun; 19(3):161-76. PubMed ID: 12945744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
